RETATRUTIDE·CONNECTICUT·VERIFIED MAY 13, 2026

Is Retatrutide legal in Connecticut?

CAVEATS APPLY

Investigational GLP-1/GIP/glucagon triple agonist; no FDA approval; FDA has issued multiple Warning Letters to vendors marketing it for human use. Connecticut AG sued Triggered Brand under CUTPA for unlicensed-pharmacy GLP-1 distribution; settled with $300,000 judgment. Reaches research-grade retatrutide distribution by analogy.

CATEGORY · INVESTIGATIONAL

Full status breakdown

FEDERAL · STATE · SPORT-BODY

Federal status

FDA approval

investigational

Indications: obesity (Phase 3 TRIUMPH); T2DM; MASH; OSA; knee OA

FDA SOURCE ↗

DEA scheduling

not scheduled

DEA ORANGE BOOK ↗

503A compounding

Bulks list: not on list

Do-not-compound list: not on list

FDA stated retatrutide cannot be lawfully compounded under §503A because it is not on the bulks list and is not a component of an approved drug.

SOURCE ↗

FDA Warning Letters

Dec 10, 2024 — Summit Research Peptides (cited: retatrutide, tirzepatide) · LETTER ↗
Dec 10, 2024 — Xcel Research LLC (cited: retatrutide, cagrilintide, mazdutide) · LETTER ↗
Sep 9, 2025 — GLP-1 Solution (cited: retatrutide) · LETTER ↗
Mar 31, 2026 — Gram Peptides (cited: retatrutide, tirzepatide) · LETTER ↗
Mar 31, 2026 — Prime Sciences (cited: retatrutide) · LETTER ↗

Shortage status

not currently on shortage list

SOURCE ↗

Sale framing

Research-use-only posture: FDA has consistently rejected 'research use only' labeling as a safe harbor when site evidence (dosing instructions, vials/syringes, comparisons to weight-loss drugs) shows human-use intent. Multiple Warning Letters cite this exact pattern for retatrutide.

Personal possession: Personal possession of unapproved investigational peptides sits in a regulatory gray zone. FDA enforcement focus has been on vendor-side marketing and sale, not buyer-side possession, but no formal safe harbor exists.

SOURCE 1 ↗SOURCE 2 ↗

Connecticut — state-specific

consumer protection action · Connecticut

Connecticut AG sued Triggered Brand under CUTPA for unlicensed-pharmacy GLP-1 distribution; settled with $300,000 judgment. Reaches research-grade retatrutide distribution by analogy.

CT AG press release — Triggered Brand suit ↗ · verified May 13, 2026

Sport-body status

WADA 2026

on prohibited list · class S2 · both

Captured under S2 (Peptide hormones, growth factors, related substances and mimetics) as a glucagon/GIP/GLP-1 triple receptor agonist; also implicated under S0 (non-approved substances).

WADA LIST ↗

USADA

banned

SOURCE ↗

NCAA

banned

SOURCE ↗

What we couldn’t verify

Also known as

7 ALIASES

Retatrutide is also marketed or referenced under the following names (vendor pseudonyms, brand names, chemical identifiers):

LY3437943
GLP-3
triple-G
GGG triple agonist
GLP-1/GIP/glucagon triple agonist
RETA
R-10mg

FOLLOW-ONS

Back to peptide legality lookup — pick a different compound or state
Retatrutide research guide — mechanism, dosing math, vendor audits, COA data
Peptide pricing index — what each compound costs per mg across audited vendors
Janoshik COA verifier — a separate question from legality: does the COA the vendor cites actually exist?

Retatrutide legality in other US states

State-by-state legal status for the same compound. Federal classification holds, state law varies.

Is Retatrutide legal in Connecticut?

Full status breakdown

Federal status

Connecticut — state-specific

Sport-body status

What we couldn’t verify

Also known as

Related

Retatrutide legality in other US states

Receipts in your inbox. Once a month.